Brain Research with CLR/TargoSphere® Nanocarrier Curcumin Targeted to Brain to treat Chronic Traumatic Encephalopathy (CTE)

Repeated head trauma, seen in military personnel and competitive sports in adults as well as in children, can lead to Chronic Traumatic Encephalopathy (CTE) with symptoms of depression, loss of emotional control, social disruption, cognitive defects, and gradual onset of dementia.

CTE is a progressive degenerative disease of the brain found in many with a history of symptomatic concussions as well as repeated asymptomatic sub-concussive traumas of all ages.

“Given the millions of contact sport athletes and military service members exposed to repetitive head impacts each year, CTE has become a major public health concern”.

Curcumin is a non-toxic compound used in foods for over 3000 years, that has been shown to have significant anti-inflammatory activities which may alleviate clinical symptoms for people with early or progressive CTE.

We have begun a preclinical Proof of Concept study to target CLR-TargoSphere® encapsulated Curcumin to immune cells that can shuttle it across the Blood Brain Barrier to cells associated with neurodegenerative changes found in CTE.

Positive findings in this study will be applied to other catastrophic neurodegenerative diseases, namely Alzheimer’s, Parkinson’s Disease, and Multiple Sclerosis.